Clinical Trial

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study acronym: PRESTO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Protocol Amendment History 3 changes
notable Enrollment reduced: 1160 -> 987 participants 2026-06-05
minor Trial arms changed: 4 -> 3 2026-06-05
notable Trial sites expanded: 363 -> 366 locations 2026-06-05
Trial Details
NCT Number NCT07082738
Lead Sponsor AstraZeneca
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 987 participants
Start Date 2025-06-27
Primary Completion 2027-11-05 (estimated)
Study Completion 2027-11-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-11